Logo

American Heart Association

  2
  0


Final ID: MDP1088

Aortic Valve Calcium as a Predictor of Chronic Kidney Disease in a Multi-Ethnic Cohort: The MESA Study

Abstract Body (Do not enter title and authors here): Background: Aortic valve calcium (AVC) is associated with an increased risk of cardiovascular disease, non-cardiovascular disease such as dementia, and all-cause mortality. Traditional atherosclerotic cardiovascular disease risk factors are associated with both AVC and chronic kidney disease (CKD), but whether there is an association between AVC and CKD is unknown.

Objectives: To ascertain whether AVC quantified by cardiac CT scanning is independently associated with the long-term risk of incident CKD among individuals without a previous history of cardiovascular disease.

Methods: We examined 6,346 Multi-Ethnic Study of Atherosclerosis (MESA) participants who underwent cardiac CT scanning at Visit 1 (2000-02) and had an eGFR of ≥ 60 mL/min/1.73 m2. AVC was quantified using the Agatston method and categorized as 0, 1-99, and ≥100. Incident CKD was defined as an eGFR < 60 mL/min/1.73 m2 accompanied with an at least 40% decline in eGFR from baseline, and/or a diagnosis of CKD and indicators of end stage renal disease extracted from hospital records using the International Classification of Disease (ICD) codes. We performed Kaplan-Meier survival curve analyses along with multivariable Cox proportional hazard regression models, adjusted for age, gender, race/ethnicity, highest level of education and traditional cardiovascular risk factors along with coronary artery calcium (CAC), lipoprotein (a) (Lp[a]), and the APOE-ε4 genotype to examine the association between AVC (categorical and log-transformed) and incident CKD.

Results: Participants had a mean age 62.2±10.1 years, 53% were women, and AVC >0 was present in 795 (12%) participants. During a median follow-up time of 16.9 years, 982 (15%) participants developed incident CKD. AVC examined as a continuous variable was associated with a significantly increased risk of developing CKD (per log-unit [AVC+1] HR 1.06 [95% CI: 1.02-1.10]; p = 0.005). There was a stepwise increased risk for CKD with higher AVC levels (Figure). Similarly, in the multivariable adjusted Cox models, participants with AVC ≥100 had a higher risk of incident CKD, compared with the AVC=0 group (HR 1.48 [95% CI: 1.15-1.89]; p = 0.002). The observed associations remained after further adjusting for CAC score (p = 0.024), Lp (a) (p = 0.004), and the APOE-ε4 genotype (p = 0.004).

Conclusions: In a multi-ethnic cohort of participants free of CKD at baseline, AVC was independently associated with a higher risk of incident CKD.
  • Abdollahi, Ashkan  ( Johns Hopkins University , Baltimore , Maryland , United States )
  • Rotter, Jerome  ( The Lundquist Institute , Torrance , California , United States )
  • Post, Wendy  ( JOHNS HOPKINS UNIVERSITY , Baltimore , Maryland , United States )
  • Blumenthal, Roger  ( JOHNS HOPKINS UNIVERSITY , Baltimore , Maryland , United States )
  • Bluemke, David  ( UW Madison Hospital , Madison , Wisconsin , United States )
  • Lima, Joao Ac  ( JOHNS HOPKINS UNIVERSITY , Baltimore , Maryland , United States )
  • Whelton, Seamus  ( Johns Hopkins University , Baltimore , Maryland , United States )
  • Sani, Maryam  ( Johns Hopkins University , Baltimore , Maryland , United States )
  • Shabani, Mahsima  ( Vanderbilt Medical Center , Nashville , Tennessee , United States )
  • Scarpa, Bruna  ( Johns Hopkins University , Baltimore , Maryland , United States )
  • Blaha, Michael  ( JOHNS HOPKINS HOSPITAL , Baltimore , Maryland , United States )
  • Wu, Colin  ( National Institutes of Health , Bethesda , Maryland , United States )
  • Ambale-venkatesh, Bharath  ( JOHNS HOPKINS UNIVERSITY , Baltimore , Maryland , United States )
  • Budoff, Matthew  ( LUNDQUIST INSTITUTE , Torrance , California , United States )
  • Strom, Jordan  ( Beth Israel Deaconess Medical Center , Milton , Massachusetts , United States )
  • Author Disclosures:
    Ashkan Abdollahi: DO NOT have relevant financial relationships | Jerome Rotter: DO NOT have relevant financial relationships | Wendy Post: DO NOT have relevant financial relationships | Roger Blumenthal: DO NOT have relevant financial relationships | David Bluemke: DO have relevant financial relationships ; Consultant:General Electric:Active (exists now) ; Consultant:Edgewise Therapeutics:Active (exists now) ; Consultant:BioMarin:Past (completed) | Joao AC Lima: DO have relevant financial relationships ; Researcher:Canon Medical Systems:Active (exists now) ; Researcher:AstraZeneca:Active (exists now) | Seamus Whelton: DO NOT have relevant financial relationships | Maryam Sani: DO NOT have relevant financial relationships | Mahsima Shabani: No Answer | Bruna Scarpa: DO NOT have relevant financial relationships | Michael Blaha: DO have relevant financial relationships ; Research Funding (PI or named investigator):Bayer:Active (exists now) ; Advisor:New Amsterdam:Expected (by end of conference) ; Advisor:Vectura:Past (completed) ; Advisor:Agepha:Active (exists now) ; Advisor:Astra Zeneca:Past (completed) ; Advisor:Eli Lilly:Active (exists now) ; Advisor:Boehringer Ingelheim:Active (exists now) ; Advisor:Roche:Past (completed) ; Advisor:Merck:Past (completed) ; Advisor:Bayer:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Advisor:Novo Nordisk:Active (exists now) ; Researcher:Amgen:Past (completed) | Colin Wu: No Answer | Bharath Ambale-Venkatesh: DO NOT have relevant financial relationships | Matthew Budoff: DO have relevant financial relationships ; Researcher:General Electric:Active (exists now) | Jordan Strom: DO have relevant financial relationships ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Consultant:Bristol Myers Squibb:Active (exists now) ; Consultant:EVERSANA:Active (exists now) ; Other (please indicate in the box next to the company name):Pfizer (clinical endpoint committee):Active (exists now) ; Advisor:EchoIQ:Active (exists now) ; Research Funding (PI or named investigator):Philips Healthcare:Active (exists now) ; Consultant:GE Healthcare:Active (exists now) ; Research Funding (PI or named investigator):Anumana:Active (exists now) ; Consultant:Bracco Diagnostics:Active (exists now) ; Advisor:HeartSciences:Active (exists now) ; Consultant:Edwards Lifesciences:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:
More abstracts on this topic:
A Comparison of Outcomes in Heart Failure Patients with and without Iron Deficiency Anemia: A National Database Analysis

Bess Olva, Quevedo Ramirez Andres, Shaka Abdultawab, Oredipe Omotola, Bello Jeremiah, Shaka Hafeez

18F-NaF and 18F-FDG and calcification predict the development of abdominal aortic aneurysms and is attenuated by drug therapy

Nakahara Takehiro, Miyazawa Raita, Iwabuchi Yu, Tonda Kai, Narula Nupoor, Strauss Harry, Narula Jagat, Jinzaki Masahiro

More abstracts from these authors:
Association of Aortic Valve Calcium with Albuminuria: The Multi-Ethnic Study of Atherosclerosis

Abdollahi Ashkan, Rotter Jerome, Post Wendy, Blumenthal Roger, Bluemke David, Lima Joao Ac, Whelton Seamus, Sani Maryam, Shabani Mahsima, Scarpa Bruna, Blaha Michael, Wu Colin, Ambale-venkatesh Bharath, Budoff Matthew, Strom Jordan

Lipoprotein(a) and Its Impact on Left Ventricular Remodeling Over a Decade: The Multi-Ethnic Study of Atherosclerosis

Abdollahi Ashkan, Tsimikas Sotirios, Lima Joao Ac, Chehab Omar, Scarpa Bruna, Whelton Seamus, Ambale-venkatesh Bharath, Wu Colin, Post Wendy, Bluemke David, Tsai Michael

You have to be authorized to contact abstract author. Please, Login
Not Available